Optimizing Protocols with Historical Clinical Trial Data to Improve the Probability of Success in CAR-T Trials

Adoptive cell therapies, which harness a patient’s own immune system to combat diseases, hold immense potential in the field of oncology. However, despite CAR-T cell therapies entering clinical trials more than a decade ago, their utilization has been limited to cases where many other treatment options have been exhausted due to challenges in clinical development and potential adverse events like Cytokine Release Syndrome and cytopenia.

Download this white paper to learn:

• How CAR-T cell therapy has emerged as a promising form of cancer treatment among adoptive cell therapy approaches
• More on the current barriers for wider adoption of CAR-T cell therapy
• How Medidata AI’s growing database of combined historical clinical trial data from CAR-T/TCE treatments enables clinical development teams

White Paper from